Literature DB >> 11170976

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

L V Gubareva1, L Kaiser, M N Matrosovich, Y Soo-Hoo, F G Hayden.   

Abstract

Volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) virus and treated with the neuraminidase (NA) inhibitor oseltamivir were monitored for the emergence of drug-resistant variants. Two (4%) of 54 resistant viruses were detected by NA inhibition assay among last-day isolates recovered from 54 drug recipients. They bore a substitution His274Tyr in the NA. Hemagglutinin (HA) variants detected in the placebo group differed from the egg-adapted inoculum virus by virtue of amino acid substitutions at residues 137, 225, or both. These variants had a higher affinity for Neu5Ac(alpha2-6)Gal-containing receptors, which are characteristic of human respiratory epithelium, than for Neu5Ac(alpha2-3)Gal-containing receptors, which are typical of chicken egg allantoic membrane. Although appearing to be more sensitive to oseltamivir in humans, the variants with increased affinity for Neu5Ac(alpha2-6)Gal receptors were less sensitive than the Neu5Ac(alpha2-3)Gal-binding variants in Madin-Darby canine kidney cells. Thus, HA affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170976     DOI: 10.1086/318537

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  116 in total

1.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.

Authors:  Yasushi Suzuki; Reiko Saito; Isamu Sato; Hassan Zaraket; Makoto Nishikawa; Tsutomu Tamura; Clyde Dapat; Isolde Caperig-Dapat; Tatiana Baranovich; Takako Suzuki; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

4.  Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Authors: 
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

5.  The effect of population structure on the emergence of drug resistance during influenza pandemics.

Authors:  Florence Débarre; Sebastian Bonhoeffer; Roland R Regoes
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

6.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

7.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

8.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

9.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Authors:  N T Wetherall; T Trivedi; J Zeller; C Hodges-Savola; J L McKimm-Breschkin; M Zambon; F G Hayden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.